Prohibition Partners’ latest report on pharmaceutical cannabis has identified two new trends in the regulation of cannabis in many western countries.
It found many regions are moving towards the use of precise medicinal cannabis products such as extracts and pharmaceuticals, with oils growing in popularity in Canada and some European nations, most likely at the expense of flower.
The US market is the exception, with flower maintaining a dominant position in most medical markets.
The second trend identified in the report is the progress of adult-use cannabis legalisation which, it states, is “already drawing some medical cannabis patients in, and will probably distil the population of patients down to those who are predominantly medical users”.
The report adds it remains unclear what form future cannabinoid therapies will take as the field is still developing and innovation is still underway.